Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.59
$0.411.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.66% | 21.51% | 16.53% | 7.18% | 0.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.66% | 21.51% | 16.53% | 7.18% | 0.11% |
| Cost of Revenue | 13.37% | 17.58% | 2.63% | 2.29% | -3.95% |
| Gross Profit | 24.05% | 22.13% | 18.89% | 8.00% | 0.75% |
| SG&A Expenses | 82.04% | 78.03% | 19.18% | 13.46% | -5.18% |
| Depreciation & Amortization | 60.71% | 60.72% | 12.35% | -7.87% | -7.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.69% | 57.10% | 12.87% | 2.77% | -5.93% |
| Operating Income | -50.73% | -29.31% | 23.92% | 17.56% | 14.27% |
| Income Before Tax | -91.48% | -63.03% | -45.87% | 63.49% | 308.59% |
| Income Tax Expenses | -92.09% | -67.96% | -23.36% | 98.14% | 6,900.76% |
| Earnings from Continuing Operations | -91.28% | -60.75% | -54.76% | 50.73% | 259.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.28% | -60.75% | -54.76% | 50.73% | 259.03% |
| EBIT | -50.73% | -29.31% | 23.92% | 17.56% | 14.27% |
| EBITDA | -4.67% | 3.06% | 18.71% | 5.33% | 4.08% |
| EPS Basic | -91.13% | -60.48% | -52.67% | 60.90% | 268.83% |
| Normalized Basic EPS | -83.86% | -50.92% | 47.65% | 71.79% | 57.93% |
| EPS Diluted | -90.11% | -61.84% | -49.46% | 52.35% | 238.80% |
| Normalized Diluted EPS | -79.98% | -49.84% | 47.83% | 70.77% | 23.22% |
| Average Basic Shares Outstanding | -1.65% | -0.69% | -4.40% | -6.32% | -5.81% |
| Average Diluted Shares Outstanding | -20.75% | -2.84% | -4.51% | -5.76% | 20.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |